Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1708 ARTÍCULOS , VIENDO DEL 331 AL 345

Molecular Mechanisms of Microglial Motility: Changes in Ageing and Alzheimer's Disease

Franco-Bocanegra DK, McAuley C, Nicoll JAR, Boche D.

Cells. 2019 Jun 25;8(6):639. doi: 10.3390/cells8060639.

[Did Alzheimer research fail entirely? : Failure of amyloid-based clinical studies]

Haass C, Levin J.

Nervenarzt. 2019 Sep;90(9):884-890. doi: 10.1007/s00115-019-0751-1.

Copper-Targeting Approaches in Alzheimer's Disease: How To Improve the Fallouts Obtained from in Vitro Studies

Esmieu C, Guettas D, Conte-Daban A, Sabater L, Faller P, Hureau C.

Inorg Chem. 2019 Oct 21;58(20):13509-13527. doi: 10.1021/acs.inorgchem.9b00995. Epub 2019 Jun 17.

Air Pollution, Combustion and Friction Derived Nanoparticles, and Alzheimer's Disease in Urban Children and Young Adults

Calderón-Garcidueñas L, González-Maciel A, Kulesza RJ, González-González LO, Reynoso-Robles R, Mukherjee PS, Torres-Jardón R.

J Alzheimers Dis. 2019;70(2):343-360. doi: 10.3233/JAD-190331.

Predicting Risk for Dementia: Is It Ready for the Clinic?

Johnson SC, Asthana S.

Am J Psychiatry. 2019 Jul 1;176(7):501-502. doi: 10.1176/appi.ajp.2019.19050520.

Cholinesterase inhibitors as Alzheimer's therapeutics (Review)

Sharma K.

Mol Med Rep. 2019 Aug;20(2):1479-1487. doi: 10.3892/mmr.2019.10374. Epub 2019 Jun 11.

Alzheimer's disease: Key developments support promising perspectives for therapy

Meldolesi J.

Pharmacol Res. 2019 Aug;146:104316. doi: 10.1016/j.phrs.2019.104316. Epub 2019 Jun 28.

Vitamin D and Psychosis in Alzheimer Disease: New Insights From Pharmacogenomics Research

Vyas CM, Okereke OI.

Am J Geriatr Psychiatry. 2019 Sep;27(9):918-919. doi: 10.1016/j.jagp.2019.05.021. Epub 2019 Jun 4.

Emerging links between cell competition and Alzheimer's disease

Coelho DS, Moreno E.

J Cell Sci. 2019 Jul 1;132(13):jcs231258. doi: 10.1242/jcs.231258.

Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis

Glinz D, Gloy VL, Monsch AU, Kressig RW, Patel C, McCord KA, Ademi Z, Tomonaga Y, Schwenkglenks M, Bucher HC, Raatz H.

Swiss Med Wkly. 2019 Jun 30;149:w20093. doi: 10.4414/smw.2019.20093. eCollection 2019 Jun 17.

Consequences of Metabolic Disruption in Alzheimer's Disease Pathology

Ryu JC, Zimmer ER, Rosa-Neto P, Yoon SO.

Neurotherapeutics. 2019 Jul;16(3):600-610. doi: 10.1007/s13311-019-00755-y.

Evaluation of the Genetic Variance of Alzheimer's Disease Explained by the Disease-Associated Chromosomal Regions

Nazarian A, Kulminski AM.

J Alzheimers Dis. 2019;70(3):907-915. doi: 10.3233/JAD-190168.

Current and emerging avenues for Alzheimer's disease drug targets

Loera-Valencia R, Cedazo-Minguez A, Kenigsberg PA, Page G, Duarte AI, Giusti P, Zusso M, Robert P, Frisoni GB, Cattaneo A, Zille M, Boltze J, Cartier N, Buee L, Johansson G, Winblad B.

J Intern Med. 2019 Oct;286(4):398-437. doi: 10.1111/joim.12959. Epub 2019 Aug 29.

Serious Illness and End-of-Life Treatments for Nurses Compared with the General Population

Bynum J, Passow H, Austin A, Carmichael D, Grodstein F.

J Am Geriatr Soc. 2019 Aug;67(8):1582-1589. doi: 10.1111/jgs.16044. Epub 2019 Jul 9.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias